}

Alvogen recalls Clindamycin Injection

07/12/2017

The FDA announced that Alvogen is voluntarily recalling seven lots of Clindamycin Injection USP APP-Vantage vials due to a possibly breach in sterility assurance during the manufacturing process. The drug is manufactured for Alvogen by Hospira. Clindamycin Injection is indicated in the treatment of serious infections caused by susceptible bacteria. Its use should be reserved for patients for whom penicillin is not appropriate. Read the FDA safety alert.

<< return to Advocacy Updates